The same week the US Supreme Court ruled that drugmakers can be sued for so-called pay-for-delay agreements, the European Commission has fined nine pharmaceutical drug companies – an unprecedented sanction – for paying to keep generic drugs off the shelves. The fines, which amount to more than $195 million, follow a report by the Commission completed in 2009 which resolved that consumers paid up to 20 percent more for prescription drugs because of these agreements. Those that were fined include Denmark-based Lundbeck and India-based Ranbaxy. In a statement, European Commissioner Joaquin Almuna told reporters that the watchdog “will not tolerate such anticompetitive practices.”
Full Content: Yahoo News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Athletes Behind NCAA Antitrust Settlement Push for Collective Bargaining Rights
Dec 11, 2024 by
CPI
Big Tech Stocks Surge as Trump Names Ferguson to Lead FTC
Dec 11, 2024 by
CPI
Synopsys Proposes Divestitures to Secure EU Approval for $35 Billion Ansys Deal
Dec 11, 2024 by
CPI
Renowned Antitrust Expert and Former Morgan Lewis Chair John Shenefield Passes Away
Dec 11, 2024 by
CPI
Trump Taps Mark Meador for Federal Trade Commission Post
Dec 11, 2024 by
CPI
Antitrust Mix by CPI
Coopetition in The Pharma Industry: Challenges for Antitrust
Dec 12, 2024 by
Juan Delgado & Lourdes Sosa
Symmetry and the Sixth Force: The Essential Role of Complements
Dec 12, 2024 by
Adam Brandenburger & Barry Nalebuff
ESG Collaborations in Light of European Antitrust Policy and Enforcement Trends
Dec 12, 2024 by
Christian Ritz, Julia Gingelmaier & Kyra Harmes
Antitrust Chronicle® – Co-opetition
Dec 11, 2024 by
CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI